Author

I. Berard

Observed names: I Berard, Izzz Berard

Institution: Nextep

Observed institution: Nextep

OpenAlex ID: A5028628616

PMD17 Comparison of Market Access Routes of Digital Health Applications in France, Germany and the UK

2020 · L. Vollmer, G. Foxon, et al. · Value in Health · 4

PPM11 Market Access Landscape for Advanced Therapy Medicinal Products in the EU-5

2020 · F. Benazet, I. Berard, et al. · Value in Health · 3

Pbi38 Innovative Atmps: Market Access and Reimbursement Decisions in the Eu5: Availability or Not, That Is the Question...

2019 · S. Walzer, M. Prada, et al. · Value in Health · 3

PDF

Pro72 Market Access, Pricing and Reimbursement Processes for Orphan Drugs in the Eu-5 Countries: a Comparative Assessment

2019 · L. Vollmer, M. Prada, et al. · Value in Health · 2

PDF

Pro80 Comparison of Early Access Programmes for Orphan Drugs in the Eu-5 Countries

2019 · W. Schleich, L. Vollmer, et al. · Value in Health · 1

Pmd148 - the Budget Impact of Global Telemedicine Solution in France

2018 · I. Berard, F. Benazet, et al. · Value in Health · 1

PDF

Time To Reimbursement For Oncology Drugs In EU5

2018 · M Prada, I Berard, et al. · Value in Health · 1

HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Committee)

2022 · E Vuong, M de Folleville, et al. · Value in Health

PDF

HTA209 Comparative Analysis of the Transparency Committee Opinions Concerning the Added Medical Benefit Levels Depending on the Therapeutic Areas: Distribution of Innovation and Trend Assessment for 2016-2021

2022 · E Bonnomet, M de Folleville, et al. · Value in Health

PRO87 Limited Target Population: IMPACT on Medical Benefit (SMR) and Improvement of Medical Benefit (ASMR) of Drugs

2020 · D. Diab, A. de Montgolfier, et al. · Value in Health

PDG57 LEVEL of Innovation According to Therapeutic Areas As per TC Opinions

2020 · D. Le Tohic, P. Gilles, et al. · Value in Health

PRO97 Orphan Drugs: Difference between Pharmaceutical Company Claims Versus Smr/Asmr Levels Granted through Analysis

2020 · D. Le Tohic, M. Guillot, et al. · Value in Health

PDG71 Comparative Analysis of the Transparency Committee Opinions Concerning the Medical Benefit of Drugs Available in EARLY Access Programs VS Other Drugs in France: 2020 Update and TREND Assesment

2020 · F. Benazet, M. Guillot, et al. · Value in Health

PDF

PDG72 Comparative Analysis of the Transparency Committee Opinions Concerning the Added Medical Benefit of Drugs Available through an EARLY Access Programs VS Others Drugs in France: 2020 Update and TREND Assesment

2020 · F. Benazet, R. Puzenat, et al. · Value in Health

PDF

Pns236 Comparative Analysis of Transparency Committee Opinion Concerning the Medical Benefit Obtained by Drugs Available in Early Access Program Vs the Others in France

2019 · F. Benazet, D. Le Tohic, et al. · Value in Health

Pro74 Time for Reimbursement for Orphan Drugs in Eu5 in the Last Three Years

2019 · M. Prada, F. Benazet, et al. · Value in Health

PDF

Pns228 Time for Reimbursement and Pricing for Drugs Depending on the Early Access Status in France (with or Without Atu)

2019 · D. Le Tohic, F. Benazet, et al. · Value in Health

Pns229 Comparative Analysis of Transparency Committee Opinion Concerning the Added Medical Benefit Obtained by Drugs Available Through Early Access Program Vs the Others

2019 · F. Benazet, D. Le Tohic, et al. · Value in Health

Pcn285 - Price Differences for Oncology Drugs Across the Eu-5 Countries: a Comparative Assessment.

2018 · M. Cuesta, M. Prada, et al. · Value in Health

Prs73 - the Budget Impact of Nicotinic Substitute Reimbursement

2018 · I. Berard, F. Benazet, et al. · Value in Health

Psy165 - Price Differences for Orphan Drugs Across the Eu-5 Countries: a Comparative Assessment

2018 · M. Brosa, M. Prada, et al. · Value in Health

Php217 - Time to Market and Price Comparison for Biosimilar Drugs in Eu5

2018 · N. López, M. Prada, et al. · Value in Health

Time for Reimbursement for Orphan Drugs in EU5

2018 · M Prada, I Berard, et al. · Value in Health

Allowing Methadone’s Prescription To General Practitioners: A Positive Impact on The French Healthcare Insurance Expenditures

2017 · Izzz Berard, F Benazet, et al. · Value in Health

Innovation : A Value For Health And Growth, An International Study On Market Access Stakes For Therapeutic Innovation

2016 · I Berard · Value in Health

Works count: 25

Citation count: 15

H-index: 3

I10-index: